FLSM
VRDN icon

Frazier Life Sciences Management’s Viridian Therapeutics VRDN Stock Holding History

Frazier Life Sciences Management’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-980,302
Closed -$11.3M – 44
2022
Q2 		$11.3M Sell
980,302
-759,228
-44% -$10.2M 1.07% 25
2022
Q1 		$32.2M Buy
+1,739,530
New +$33.4M 2.74% 12

Other funds holding VRDN

CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Frazier Life Sciences Management's VRDN Position: Q3 2022 in Review

Frazier Life Sciences Management sold out of Viridian Therapeutics (VRDN) in Q3 2022, closing a stake of 980,302 shares — an estimated $11.3M sold.

Frazier Life Sciences Management first reported a position in VRDN in Q1 2022 and held it in 2 quarters. The position peaked at $32.2M in Q1 2022. 105 funds tracked by Wall St. Rank hold VRDN as of Q3 2022.

  • Frazier Life Sciences Management reported no remaining Viridian Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Frazier Life Sciences Management sold 980,302 Viridian Therapeutics shares in Q3 2022, an estimated $11.3M.
  • Frazier Life Sciences Management first reported a position in Viridian Therapeutics in Q1 2022 and held it in 2 quarters.
  • Frazier Life Sciences Management's Viridian Therapeutics position peaked at $32.2M in Q1 2022.
  • 105 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q3 2022.

Based on Frazier Life Sciences Management's 13F filing for Q3 2022, filed 14 Nov 2022.